Nursing care
Sulfonylureas: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated September 2026
Short answer
Sulfonylureas lower blood glucose by stimulating the pancreas to release more insulin, which means they can cause hypoglycaemia — a risk metformin does not carry. Check blood glucose before dosing, give with the first bite of a meal, and watch for sweating, confusion, and tremor, especially in older adults or anyone skipping meals.
Mechanism, simply
Sulfonylureas bind to ATP-sensitive potassium channels on pancreatic beta cells. Closing those channels depolarises the cell, opens voltage-gated calcium channels, and triggers insulin release. The drug only works if the pancreas can still produce insulin, which is why it has no role in type 1 diabetes.
This mechanism is insulin-independent of the patient's own glucose level in the way metformin's action is not. Metformin reduces hepatic glucose output and improves insulin sensitivity without forcing insulin release, so it rarely causes hypoglycaemia on its own. A sulfonylurea pushes insulin out regardless of how much glucose is actually in the blood at that moment, and that is the property behind nearly every safety question written about this drug class.
Indications you will see on the ward
Glipizide and glyburide are prescribed for type 2 diabetes when diet, exercise, and metformin have not brought glucose to target, or when metformin is contraindicated by renal impairment. You will see them alone or combined with metformin, and occasionally with insulin in more advanced disease.
They are second- or third-line in most current guidance because of the hypoglycaemia risk and a tendency toward weight gain. Expect to see glipizide favoured over glyburide in older patients, since glyburide has a longer half-life and active metabolites that accumulate with reduced renal clearance.
Assessment before administration
Check blood glucose immediately before the dose. If it is already low or the patient has not eaten, hold the dose and notify the prescriber rather than giving it on schedule. Ask directly whether the patient plans to eat within the next 30 minutes — the drug is timed to a meal, not to the clock.
Review renal and hepatic function. Both organs clear sulfonylureas and their active metabolites, and impairment in either prolongs drug exposure and raises hypoglycaemia risk. Confirm the patient does not have a sulfa allergy, since sulfonylureas share a chemical relationship with sulfonamide antibiotics and can cross-react in sensitive patients.
Toxicity and the antidote
Hypoglycaemia is the toxicity that matters clinically. Early signs are sweating, tremor, tachycardia, and hunger; as glucose falls further, confusion, slurred speech, and loss of consciousness follow. Because glyburide and extended-release glipizide can act for many hours, hypoglycaemia from these drugs is often prolonged and can recur after initial treatment.
There is no pharmacological antidote — management is glucose replacement. Give 15 to 20 grams of fast-acting oral carbohydrate if the patient is alert and can swallow safely, recheck glucose in 15 minutes, and repeat if still low. For a patient who cannot swallow or is unconscious, give IV dextrose or IM/subcutaneous glucagon per protocol, then keep monitoring for hours afterward because sulfonylurea-induced hypoglycaemia relapses more often than insulin-induced hypoglycaemia does.
Interactions that matter
Alcohol increases hypoglycaemia risk and can also produce a disulfiram-like flushing reaction with some sulfonylureas. Warn patients about drinking, and ask about intake as part of your assessment rather than assuming it will come up unprompted.
Beta-blockers blunt the adrenergic warning signs of hypoglycaemia — the tremor and tachycardia a patient would otherwise notice — so hypoglycaemia can progress further before it is recognised. NSAIDs, sulfonamide antibiotics, and warfarin can displace sulfonylureas from protein binding or slow their clearance, intensifying the glucose-lowering effect. Any new drug that itself lowers glucose, such as insulin or another oral antidiabetic, compounds the risk when added to an existing sulfonylurea regimen.
What the patient must be told
Take the dose with the first bite of a meal, never on an empty stomach, and never skip a meal after taking it. Missing food after dosing is the single most common cause of a hypoglycaemic episode at home.
Teach the patient to recognise early hypoglycaemia — shakiness, sweating, sudden hunger, irritability — and to treat it immediately with fast-acting carbohydrate rather than waiting to see if it passes. Advise carrying a glucose source at all times and wearing medical identification. Limit alcohol, and tell the patient to call their prescriber before starting any new medication, since several common drug classes intensify the glucose-lowering effect.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our endocrine practice questions are the closest set to what this page covers.
Common questions
Do sulfonylureas cause hypoglycaemia like insulin does?
Yes. Sulfonylureas stimulate insulin release regardless of the patient's actual glucose level, so hypoglycaemia is a real and expected risk, not a rare side effect. This is the key distinction from metformin, which does not typically cause hypoglycaemia on its own.
What is the antidote for sulfonylurea overdose?
There is no drug antidote. Treatment is glucose: oral carbohydrate if the patient can swallow, or IV dextrose and glucagon if not. Because glyburide and glipizide can act for many hours, monitor glucose for an extended period after treatment, since it can drop again.
Why are sulfonylureas given with food?
The dose is timed to trigger insulin release around a meal. Taking it without food, or skipping the meal afterward, releases insulin with no incoming glucose to match it, which precipitates hypoglycaemia.
Can a patient with a sulfa allergy take glipizide or glyburide?
Use caution and confirm with the prescriber. Sulfonylureas share a chemical structure with sulfonamide antibiotics, and cross-reactivity has been reported, so a documented sulfa allergy should be flagged before the first dose.
Why do beta-blockers matter with sulfonylureas?
Beta-blockers mask the adrenergic symptoms of hypoglycaemia, such as tremor and a racing heart, that would normally alert the patient early. That can let glucose fall further before anyone notices, so glucose monitoring becomes more important, not less, when the two drugs are combined.